

Michael A Quinn

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7513197/michael-a-quinn-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

8,409
citations

46
h-index

89
g-index

169
ext. papers

9,511
ext. citations

5.1
avg. IF

5.54
L-index

#	Paper	IF	Citations
160	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4	890
159	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 928-36	21.7	475
158	Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg). <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 419-23	3.5	400
157	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 295-309	21.7	263
156	Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). <i>Journal of the National Cancer Institute</i> , 2004 , 96, 487-8	9.7	221
155	Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. <i>International Journal of Cancer</i> , 1995 , 62, 678-84	7.5	205
154	Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. <i>Journal of Cellular Physiology</i> , 2007 , 213, 581-8	7	192
153	Chapter 8: Screening for cervical cancer in developing countries. <i>Vaccine</i> , 2006 , 24 Suppl 3, S3/71-7	4.1	188
152	An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. <i>Proteomics</i> , 2003 , 3, 1980-7	4.8	178
151	Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. <i>Current Cancer Drug Targets</i> , 2010 , 10, 268-78	2.8	178
150	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. <i>Journal of Cellular Biochemistry</i> , 2011 , 112, 2850-64	4.7	173
149	Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. <i>American Journal of Physiology - Cell Physiology</i> , 2006 , 290, C1532-42	5.4	157
148	Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. <i>PLoS ONE</i> , 2012 , 7, e46858	3.7	154
147	Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. <i>Journal of Clinical Oncology</i> , 2014 , 32, 90-100	2.2	149
146	Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. <i>Molecular Cancer</i> , 2013 , 12, 24	42.1	147
145	Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. <i>BioMed Research International</i> , 2015 , 2015, 413076	3	143
144	Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. <i>International Journal of Cancer</i> , 2007 , 120, 2426-34	7.5	143

143	FTIR microspectroscopic study of cell types and potential confounding variables in screening for cervical malignancies 1998 , 4, 75-91		137
142	Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. <i>Vaccine</i> , 2004 , 23, 172-81	4.1	135
141	Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. <i>International Journal of Cancer</i> , 1997 , 71, 948-51	7.5	121
140	Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. <i>Cancer</i> , 2002 , 94, 1466-75	6.4	111
139	Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. <i>Journal of Pathology</i> , 2003 , 201, 229-37	9.4	111
138	The impact of PET/CT in the management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 103, 271-6	4.9	110
137	Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. <i>Clinical and Experimental Metastasis</i> , 2005 , 22, 391-402	4.7	104
136	Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. <i>Gynecologic Oncology</i> , 2000 , 79, 207-10	4.9	93
135	Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. <i>Journal of Carcinogenesis</i> , 2007 , 6, 11	1.9	92
134	Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2002 , 50, 1371-80	3.4	86
133	An investigation into FTIR spectroscopy as a biodiagnostic tool for cervical cancer. <i>Biospectroscopy</i> , 1998 , 2, 143-153		84
132	Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. <i>BMC Cancer</i> , 2014 , 14, 317	4.8	83
131	Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. <i>Proteomics</i> , 2005 , 5, 4625-36	4.8	82
130	Low dose cyclophosphamide: Mechanisms of T cell modulation. <i>Cancer Treatment Reviews</i> , 2016 , 42, 3-9	14.4	81
129	Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. <i>Gynecologic Oncology</i> , 2015 , 136, 87-93	4.9	81
128	Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. <i>Clinical Immunology</i> , 2013 , 149, 97-110	9	80
127	A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. <i>Clinical Cancer Research</i> , 2005 , 11, 1890-8	12.9	80
126	Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. <i>Gynecologic Oncology</i> , 2007 , 107, 424-30	4.9	77

125	First-line therapy in ovarian cancer trials. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 756-62	3.5	75
124	Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. <i>Journal of Cellular Biochemistry</i> , 2013 , 114, 21-34	4.7	73
123	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. <i>Cancer Research</i> , 2012 , 72, 4060-73	10.1	73
122	Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 2130-7	9.7	73
121	Serum HE4 as a prognostic marker in endometrial cancer--a population based study. <i>Gynecologic Oncology</i> , 2014 , 132, 159-65	4.9	72
120	CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?. <i>Journal of Translational Medicine</i> , 2009 , 7, 102	8.5	67
119	Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women. <i>Obstetrics and Gynecology</i> , 1997 , 89, 88-93	4.9	65
118	Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. <i>Gynecologic Oncology</i> , 2017 , 146, 623-629	4.9	59
117	Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. <i>Vaccine</i> , 2008 , 26 Suppl 12, M71-9	4.1	55
116	Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 2002 , 84, 675-86	4.7	49
115	Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. <i>Psycho-Oncology</i> , 2013 , 22, 2071-8	3.9	47
114	Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. <i>Supportive Care in Cancer</i> , 2015 , 23, 2215-24	3.9	46
113	Endometrial cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012 , 26, 311-24	4.6	45
112	Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. <i>Journal of Ovarian Research</i> , 2012 , 5, 37	5.5	45
111	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. <i>Medical Journal of Australia</i> , 2014 , 201, 283-8	4	44
110	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. <i>Frontiers in Oncology</i> , 2014 , 4, 75	5.3	44
109	A three-dimensional multivariate image processing technique for the analysis of FTIR spectroscopic images of multiple tissue sections. <i>BMC Medical Imaging</i> , 2006 , 6, 12	2.9	44
108	The absence of genital human papillomavirus DNA in virginal women. <i>International Journal of STD and AIDS</i> , 1992 , 3, 414-7	1.4	44

107	Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. <i>Current Medicinal Chemistry</i> , 2018 , 25, 4785-4806	4.3	44
106	Quality of life of women with lower limb swelling or lymphedema 3-5 years following endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 133, 314-8	4.9	43
105	Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 2415-20	12.9	41
104	Is there any value in bimanual pelvic examination as a screening test?. <i>Medical Journal of Australia</i> , 1995 , 162, 408-410	4	41
103	Persistent trophoblast disease following partial molar pregnancy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 119-23	1.7	39
102	Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. <i>Frontiers in Immunology</i> , 2017 , 8, 1482	8.4	34
101	HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. <i>Journal of Medical Virology</i> , 2009 , 81, 1283-91	19.7	32
100	Ovarian cancer: patterns of care in Victoria during 1993-1995. <i>Medical Journal of Australia</i> , 2002 , 177, 11-6	4	32
99	Hormonal therapies and gynaecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2008 , 22, 407-21	4.6	31
98	Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. <i>Gynecologic Oncology</i> , 2001 , 82, 64-8	4.9	31
97	Does experience in colposcopy improve identification of high grade abnormalities?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008 , 141, 75-8	2.4	30
96	A clinicopathologic study of glandular dysplasia of the cervix. <i>Gynecologic Oncology</i> , 1997 , 64, 166-70	4.9	29
95	Removal of blood components from cervical smears: implications for cancer diagnosis using FTIR spectroscopy. <i>Biopolymers</i> , 2003 , 72, 69-76	2.2	27
94	A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. <i>Molecular Cancer</i> , 2015 , 14, 152	42.1	25
93	Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). <i>Gynecologic Oncology</i> , 2012 , 126, 36-40	4.9	25
92	Phase II trial of VP-16-213 in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1985 , 22, 162-6	4.9	25
91	A new prognostic model for FIGO stage 1 epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2007 , 104, 607-11	4.9	24
90	Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. <i>Gynecologic Oncology</i> , 2004 , 92, 80-8	4.9	24

89	Fourier Transform Infrared Imaging and Unsupervised Hierarchical Clustering Applied to Cervical Biopsies. <i>Australian Journal of Chemistry</i> , 2004 , 57, 1139	1.2	24
88	2D-PAGE of ovarian cancer: analysis of soluble and insoluble fractions using medium-range immobilized pH gradients. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 406, 408-13	3.4	23
87	Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer. <i>General Hospital Psychiatry</i> , 2014 , 36, 74-80	5.6	22
86	Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. <i>Gynecologic Oncology</i> , 2003 , 90, 318-24	4.9	22
85	Collision tumor: serous adenocarcinoma and steroid cell tumor of the ovary. <i>Pathology</i> , 1992 , 24, 60-2	1.6	22
84	A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer 2014 , 2, 16		21
83	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. <i>Gynecologic Oncology</i> , 2017 , 147, 381-387	4.9	21
82	Transabdominal cervical cerclage. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2010 , 50, 460-4	1.7	21
81	Embodied changes and the search for gynecological cancer diagnosis. <i>Medical Anthropology Quarterly</i> , 2004 , 18, 376-96	2.5	21
80	Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. <i>Proteomics</i> , 2003 , 3, 288-98	4.8	21
79	Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment?. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 1166-9	3.5	21
78	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 417-21	4.9	20
77	Influence of benign cellular changes in diagnosis of cervical cancer using IR microspectroscopy. <i>Biopolymers</i> , 2002 , 67, 362-6	2.2	20
76	"Like roulette": Australian women's explanations of gynecological cancers. <i>Social Science and Medicine</i> , 2005 , 61, 323-32	5.1	20
75	Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia. <i>Journal of Clinical Virology</i> , 2015 , 62, 63-5	14.5	19
74	Endometrial cancer risk and survival by tumor MMR status. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e39	4	19
73	Oral cyclophosphamide in recurrent ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12, e154-60	1.9	18
72	Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. <i>Breast</i> , 2016 , 26, 100-5	3.6	18

71	Complementary medicine use by Australian women with gynaecological cancer. <i>Psycho-Oncology</i> , 2006 , 15, 209-20	3.9	17
70	Clearance of human papillomavirus in women treated for cervical dysplasia. <i>Obstetrics and Gynecology</i> , 2011 , 117, 101-108	4.9	16
69	Curarisation of fetus for intrauterine procedures. <i>Lancet, The</i> , 1985 , 1, 1164	4.0	15
68	Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 264-7	3.5	14
67	Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas. <i>Molecular Carcinogenesis</i> , 2003 , 37, 61-4	5	14
66	Labour induction with low dose PGE2 vaginal gel: result of an Australian multicentre randomized trial. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1989 , 29, 124-8	1.7	14
65	Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 75-81	3.5	13
64	Guidelines following hydatidiform mole: a reappraisal. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 112-8	1.7	13
63	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. <i>Acta Oncologica</i> , 2016 , 55, 226-33	3.2	12
62	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017 , 28, e54	4	12
61	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. <i>Journal of Translational Medicine</i> , 2014 , 12, 179	8.5	12
60	Hereditary gynecologic cancers. <i>International Journal of Gynecology and Obstetrics</i> , 2014 , 124, 189-92	4	12
59	'He's telling us something'. <i>Anthropology and Medicine</i> , 2004 , 11, 327-41	1.1	11
58	Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. <i>Cancers</i> , 2012 , 4, 581-600	6.6	10
57	Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2009 , 49, 426-8	1.7	10
56	Expression and localization of alphavbeta6 integrin in extraplacental fetal membranes: possible role in human parturition. <i>Molecular Human Reproduction</i> , 2004 , 10, 173-9	4.4	10
55	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5632-TPS5632	2.2	10
54	An alternative cost effectiveness analysis of ThinPrep in the Australian setting. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005 , 45, 289-94	1.7	9

53	Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer 1997 , 71, 948		9
52	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1811-1823	3.5	8
51	Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. <i>Gynecologic Oncology</i> , 2001 , 81, 216-24	4.9	8
50	Hormonal treatment of endometrial cancer. <i>Hematology/Oncology Clinics of North America</i> , 1999 , 13, 163-87, ix	3.1	8
49	HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017 , 4, 79-84	4.6	7
48	Long-term outcomes after progestogen treatment for early endometrial cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2013 , 53, 566-70	1.7	7
47	Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 1290-8	3.5	7
46	Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. <i>Journal of Ovarian Research</i> , 2010 , 3, 17	5.5	7
45	Study Protocol for Informing American Muslims about Organ Donation (I AM a LD) 2, 1-17		7
44	Coalition of Oct4A and β integrins in facilitating metastasis in ovarian cancer. <i>BMC Cancer</i> , 2016 , 16, 432	4.8	5
43	Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2013 , 17, 308-14	3.6	5
42	Infrared imaging of normal and diseased cervical tissue sections 2005 ,		5
41	Women with a pelvic mass--when to perform an ultrasound. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1993 , 33, 404-7	1.7	5
40	Renal Replacement Knowledge and Preferences for African Americans With Chronic Kidney Disease. <i>Journal of Renal Care</i> , 2020 , 46, 151-160	1.6	4
39	Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2014 , 54, 453-6	1.7	4
38	Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve. <i>Gynecologic Oncology</i> , 2014 , 133, 542-5	4.9	4
37	CHAPTER 11 How to manage and communicate with patients about HPV?. <i>International Journal of Gynecology and Obstetrics</i> , 2006 , 94 Suppl 1, S106-S112	4	4
36	Treatment decisions: a qualitative study with women with gynaecological cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 46-8	1.7	4

35	Women with low-grade abnormalities on Pap smear should be referred for colposcopy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004 , 44, 252-5	1.7	4
34	Should the Pap smear be repeated at the first colposcopy visit?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005 , 45, 514-7	1.7	4
33	Fetal intravascular transfusion for severe erythroblastosis: effects on haematology and survival. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1986 , 26, 192-5	1.7	4
32	"Spurious" labour - does it matter?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1981 , 21, 167-9	1.7	4
31	The Development and Validation of the Islamic Knowledge of Living Organ Donation Knowledge Scale for Measuring Organ Donation Knowledge Among Muslim Communities. <i>Progress in Transplantation</i> , 2020 , 30, 315-321	1.1	4
30	The impact of religiously tailored and ethically balanced education on intention for living organ donation among Muslim Americans. <i>Clinical Transplantation</i> , 2020 , 34, e14111	3.8	3
29	Reply to J. Moline et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2278-9	2.2	3
28	PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS5614-TPS5614	2.2	3
27	Cotyledonoid dissecting leiomyoma. <i>Pathology</i> , 2003 , 35, 177-179	1.6	3
26	Informing American Muslims about living donation through tailored health education: A randomized controlled crossover trial evaluating increase in biomedical and religious knowledge. <i>American Journal of Transplantation</i> , 2021 , 21, 1227-1237	8.7	3
25	Evaluation of p16INK4a immunostaining for the detection of high-grade changes in cervical cytology. <i>Pathology</i> , 2015 , 47, 314-9	1.6	2
24	A phase II trial of carboplatin and etoposide for relapsed or metastatic carcinoma of the cervix. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1998 , 38, 87-90	1.7	2
23	Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE. <i>Clinical Proteomics</i> , 2007 , 3, 22-29	5	2
22	Genistein-induced proteome changes in the human endometrial carcinoma cell line, ishikawa. <i>Clinical Proteomics</i> , 2006 , 2, 153-167	5	2
21	Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020 , 60, 123-129	1.7	2
20	FTIR microspectroscopic study of cell types and potential confounding variables in screening for cervical malignancies 1998 , 4, 75		2
19	Clearance of Human Papillomavirus in Women Treated for Cervical Dysplasia. <i>Obstetrics and Gynecology</i> , 2011 , 118, 166	4.9	1
18	Benign endocervical cystic glandular change mimicking minimal deviation adenocarcinoma of the cervix on magnetic resonance imaging: a case report. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004 , 44, 358-9	1.7	1

17	Screening the high risk patient for gynaecological cancer. <i>Yonsei Medical Journal</i> , 2002 , 43, 717-21	3	1
16	Southern blot and dot blot hybridisation compared to PCR for the detection of human papillomavirus DNA in biopsies of the uterine cervix from women with dysplasia. <i>Clinical and Diagnostic Virology</i> , 1993 , 1, 187-94		1
15	The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5627-TPS5627	2.2	1
14	The IGCS global curriculum mentorship and training program: building human capacity for gynecologic cancer treatment and research where the need is greatest. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1380-1381	3.5	1
13	Findings and Outcomes in a Prevacination Cohort of Women Younger Than 25 Years Attending a Tertiary Colposcopy Service. <i>Journal of Lower Genital Tract Disease</i> , 2016 , 20, 224-9	3.6	1
12	The Prevalence, Incidence, and Quality-of-Life Impact of Lymphedema After Treatment for Vulvar or Vaginal Cancer. <i>Rehabilitation Oncology</i> , 2018 , 36, 48-55	0.8	1
11	Cervical screening in the 21st century. <i>Journal of the Medical Association of Thailand = Chotmai het Thangphaet</i> , 2004 , 87 Suppl 3, S94-5		1
10	Complex endometrial hyperplasia in the context of tibolone administration. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2009 , 49, 338-9	1.7	0
9	Reaching the women with the greatest needs: Two models for initiation and scale-up of gynecologic oncology fellowship trainings in low-resource settings. <i>International Journal of Gynecology and Obstetrics</i> , 2021 , 155 Suppl 1, 115-122	4	0
8	COVID 19 vaccination lessons from Japanese anti-HPV vaccination lobby. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1255	3.5	0
7	Two viral infections in Japan. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1258-1259	3.5	0
6	A response to the forgotten fallopian tube. <i>Nature Reviews Cancer</i> , 2011 , 11, 227-227	31.3	
5	Is colposcopy needed following laser ablation for dysplasia?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 375-8	1.7	
4	Multidisciplinary care for women with early breast cancer in the Australian context. <i>Medical Journal of Australia</i> , 2004 , 180, 429-430	4	
3	Screening and prevention of gynaecological cancer. <i>Reviews in Gynaecological Practice</i> , 2003 , 3, 148-155		
2	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5621-TPS5621	2.2	
1	Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-18	3.6	